期刊文献+

脂调康胶囊对高脂血症患者血清胆红素影响的临床研究 被引量:1

下载PDF
导出
摘要 目的:观察脂调康胶囊对高脂血症(HLP)患者血清胆红素(TBil)的影响.方法:将186例HLP患者随机分为2组.治疗组124例口服脂调康胶囊(主要由橘络、清半夏、泽泻、丹参、姜黄、虎杖、炙黄芪、炒白术等组成),对照组62例口服脂必妥片.2组均以8周为1疗程.主要观察治疗前后血清胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)、胆红素(TBil)等指标的变化.结果:2组治疗后TC、TG、LDL-C均较治疗前显著下降(P<0.01),治疗组HDL-C显著增高(P<0.01).2组治疗后比较,差异有非常显著性意义(P<0.01).治疗组治疗后血清TBil含量较治疗前显著升高(P<0.01),对照组治疗后亦较治疗前有所升高(P<0.05).结论:脂调康胶囊通过升高HLP患者血清TBil的含量,抑制低密度脂蛋白氧化修饰,有效调节血脂,防止动脉粥样硬化等疾病的形成.
出处 《新中医》 CAS 北大核心 2004年第10期20-21,共2页 New Chinese Medicine
基金 河北省卫生厅科研项目
  • 相关文献

参考文献8

  • 1Marilena G. New physiological importance of two classic residual products: carbon monoxide and bilirubin[J ]. Biochem Mol Med, 1997,61:136 - 142.
  • 2Cao G, A lessio HM, Cutler RG. Oxygen radical absorbance capacity assay for antioxidants[J]. Free Radic Biol Med,1993, 14(3): 303 - 311.
  • 3Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease[J]. Clin Chem, 2000, 46(9):1723 - 1727.
  • 4Naziroglu M, Cay M, Ustundag B. Proteeive effects of vitamin E on carbon tetrachloride induced liver damage in rats[J].Cell Biochem Funct, 1999, 17:253 -259.
  • 5Amit Y, Boneh A. Bilirubin inhibits protein kinase C activity and protein kinase C mediated phosphorylation of endogenous substrates in human skin fibroblasts[J]. Clin Chem Acta,1993, 223:103 - 111.
  • 6杨牧祥,田元祥,刘建东,张素英,冀绪,刘玉洁,高功军,王秉岳.脂调康胶囊治疗高脂血症多中心临床观察[J].河北中医药学报,2003,18(4):6-9. 被引量:6
  • 7杨牧祥,李莉,田元祥,马全庆,李荣彦,曹刚.脂调康胶囊对高脂血症大鼠血脂的调节作用观察[J].河北中医,2000,22(11):871-873. 被引量:14
  • 8中华人民共和国卫生部.中药新药临床研究指导原则[S]·第2辑[M].,1995.171-174.

二级参考文献4

共引文献17

同被引文献10

  • 1崔征,张蕾,宋明辉.潜水员潜水工龄与血清胆红素水平的关系[J].中华航海医学与高气压医学杂志,2005,12(3):183-183. 被引量:6
  • 2宋明辉,曹国强,张丽梅,曾媛,崔征,卜晓红,李净.飞行员血清胆红素与血脂水平变化的关系[J].中华航空航天医学杂志,2006,17(1):51-52. 被引量:14
  • 3曹国强,李淼,宋明辉,崔征,曾媛.飞行员血清胆红素水平变化的临床价值[J].中国疗养医学,2006,15(5):375-376. 被引量:4
  • 4Vaziri ND, Liang K, Parks JS. Acquired lecithin-cholesterol acyhransferase deficiency in nephrotic syndrome[J]. Am J Physiol, 2001, 280(5): F823-F828.
  • 5de Sain van der Velden MG, Kaysen GA, Barrett HA, et al. Increased VLDL in nephrotic patients results from a decreased ca tabolism while increased LDL results from increased synthesis [J]. Kidney Int, 1998, 53(4) : 994-1001.
  • 6Gregory C, Shearer GC, Stevenson FT, et al. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome[J]. Kidney Int, 2001, 59(1): 179-189.
  • 7Wu TW,Fung KP,Yang CC. Unconjuated bilinrubin inhibts the oxidation of human low density lipoprotein better than Trolox [J]. Life Sci, 1994,54: 477-481.
  • 8Hunt SC, Kronenberg F, Eckfeldt JH, et al. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study[J]. Atherosclerosis, 2001, 154(3): 747-754.
  • 9Kronenberg F, Coon H, Gutin A, et al. A genome scan for loci influencing antiatherogenic serum bilirubin levels[J]. Eur J Hum Genet, 2002, 10 (9): 539.
  • 10Lin JP,Lupples LA, Wilson PW. Evidence for a gene influencing serum bilirubin on chromosome Zq telomere:a genomeuide scan in the Framingham study[J]. Am J Hum Genet,2003,72(4) : 1029- 1034.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部